Reno-Protective Effect of Low Protein Diet Supplemented With α-Ketoacid Through Gut Microbiota and Fecal Metabolism in 5/6 Nephrectomized Mice

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2022 Jul 18

PMID 35845811

Authors

Yifan Zhu

Haidong He

Yuyan Tang

Yinshun Peng

Ping Hu

Weiqian Sun

Ping Liu

Meiping Jin

Xudong Xu

Affiliations

Soon will be listed here.

Abstract

Background: Low protein supplemented with α-ketoacid diet (LKD) was recommended to be an essential intervention to delay the progression of chronic kidney disease (CKD) in patients who were not yet on dialysis. Aberrant gut microbiota and metabolism have been reported to be highly associated with CKD. However, the effect of LKD on gut microbiota and related fecal metabolism in CKD remains unclear.

Methods: Mice were fed with normal protein diet (NPD group), low protein diet (LPD group), and low protein diet supplemented with α-ketoacid (LKD group) after 5/6 nephrectomy. At the end of the study, blood, kidney tissues, and feces were collected for biochemical analyses, histological, 16S rRNA sequence of gut microbiome, and untargeted fecal metabolomic analyses.

Results: Both LKD and LPD alleviate renal failure and fibrosis, and inflammatory statement in 5/6 nephrectomized mice, especially the LKD. In terms of gut microbiome, LKD significantly improved the dysbiosis induced by 5/6Nx, representing increased α-diversity and decreased F/B ratio. Compared with NPD, LKD significantly increased the abundance of , and , and decreased and . Moreover, 5/6Nx and LKD significantly altered fecal metabolome. Then, multi-omics analysis revealed that specific metabolites involved in glycerophospholipid, purine, vitamin B6, sphingolipid, phenylalanine, tyrosine and tryptophan biosynthesis, and microbes associated with LKD were correlated with the amelioration of CKD.

Conclusion: LKD had a better effect than LPD on delaying renal failure in 5/6 nephrectomy-induced CKD, which may be due to the regulation of affecting the gut microbiome and fecal metabolic profiles.

Citing Articles

Comparative Analysis of Gut Microbiomes in Laboratory Chinchillas, Ferrets, and Marmots: Implications for Pathogen Infection Research.

Guo J, Shi W, Li X, Yang B, Qin C, Su L Microorganisms. 2024; 12(4).

PMID: 38674591 PMC: 11051751. DOI: 10.3390/microorganisms12040646.

Causal relationship between gut microbiota and kidney diseases: a two-sample Mendelian randomization study.

Feng Z, Zhang Y, Lai Y, Jia C, Wu F, Chen D Front Immunol. 2024; 14:1277554.

PMID: 38283353 PMC: 10811222. DOI: 10.3389/fimmu.2023.1277554.

Genetic evidence supporting the causal role of gut microbiota in chronic kidney disease and chronic systemic inflammation in CKD: a bilateral two-sample Mendelian randomization study.

Ren F, Jin Q, Jin Q, Qian Y, Ren X, Liu T Front Immunol. 2023; 14:1287698.

PMID: 38022507 PMC: 10652796. DOI: 10.3389/fimmu.2023.1287698.

References

Conlon M, Bird A . The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2014; 7(1):17-44. PMC: 4303825. DOI: 10.3390/nu7010017. View

Zhai Q, Feng S, Arjan N, Chen W . A next generation probiotic, . Crit Rev Food Sci Nutr. 2018; 59(19):3227-3236. DOI: 10.1080/10408398.2018.1517725. View

Bellizzi V, Di Iorio B, De Nicola L, Minutolo R, Zamboli P, Trucillo P . Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2006; 71(3):245-51. DOI: 10.1038/sj.ki.5001955. View

Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G . Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017; 5(1):14. PMC: 5286796. DOI: 10.1186/s40168-016-0222-x. View

Haas B, Gevers D, Earl A, Feldgarden M, Ward D, Giannoukos G . Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 2011; 21(3):494-504. PMC: 3044863. DOI: 10.1101/gr.112730.110. View

Weiner I, Mitch W, Sands J . Urea and Ammonia Metabolism and the Control of Renal Nitrogen Excretion. Clin J Am Soc Nephrol. 2014; 10(8):1444-58. PMC: 4527031. DOI: 10.2215/CJN.10311013. View

Zhang J, Guo Z, Xue Z, Sun Z, Zhang M, Wang L . A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles, geography and ethnicities. ISME J. 2015; 9(9):1979-90. PMC: 4542028. DOI: 10.1038/ismej.2015.11. View

Tang W, Wang Z, Kennedy D, Wu Y, Buffa J, Agatisa-Boyle B . Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015; 116(3):448-55. PMC: 4312512. DOI: 10.1161/CIRCRESAHA.116.305360. View

Gui T, Li Y, Zhang S, Alecu I, Chen Q, Zhao Y . Oxidative stress increases 1-deoxysphingolipid levels in chronic kidney disease. Free Radic Biol Med. 2021; 164:139-148. DOI: 10.1016/j.freeradbiomed.2021.01.011. View

10.

Hasan A, von Websky K, Reichetzeder C, Tsuprykov O, Gaballa M, Guo J . Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy. Kidney Int. 2019; 95(6):1373-1388. DOI: 10.1016/j.kint.2019.01.010. View

11.

Williams M, Bolton W, Khalifah R, Degenhardt T, Schotzinger R, McGill J . Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007; 27(6):605-14. DOI: 10.1159/000108104. View

12.

Skrypnyk N, Voziyan P, Yang H, de Caestecker C, Theberge M, Drouin M . Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury. Am J Physiol Renal Physiol. 2016; 311(2):F268-77. PMC: 5008672. DOI: 10.1152/ajprenal.00056.2016. View

13.

Ren Z, Fan Y, Li A, Shen Q, Wu J, Ren L . Alterations of the Human Gut Microbiome in Chronic Kidney Disease. Adv Sci (Weinh). 2020; 7(20):2001936. PMC: 7578882. DOI: 10.1002/advs.202001936. View

14.

Rapa S, Di Iorio B, Campiglia P, Heidland A, Marzocco S . Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. Int J Mol Sci. 2020; 21(1). PMC: 6981831. DOI: 10.3390/ijms21010263. View

15.

Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L . A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2016; 23(1):107-113. DOI: 10.1038/nm.4236. View

16.

Zmora N, Suez J, Elinav E . You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2018; 16(1):35-56. DOI: 10.1038/s41575-018-0061-2. View

17.

Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S . Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019; 25(7):1096-1103. PMC: 6699990. DOI: 10.1038/s41591-019-0495-2. View

18.

Zhou L, Ni Z, Yu J, Cheng W, Cai Z, Yu C . Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2020; 11:628. PMC: 7505924. DOI: 10.3389/fendo.2020.00628. View

19.

Ebert T, Neytchev O, Witasp A, Kublickiene K, Stenvinkel P, Shiels P . Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. Antioxid Redox Signal. 2021; 35(17):1426-1448. DOI: 10.1089/ars.2020.8184. View

20.

Ponticelli C, Podesta M, Moroni G . Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. Kidney Int. 2020; 98(5):1149-1159. DOI: 10.1016/j.kint.2020.05.056. View